SOL J BARER
CIK 1247015 · Executive Chairman · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$51.74M
Companies
17
Total Filings
157
Lifetime Open-Market Net
-$126.37M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TEVA | Director | 448,011 | $31.67 | $14.19M | $2.00M | 22 | 2026-06-08 |
| NexImmune, Inc. (NEXI) Delisted | Director | 150,234 | $0.00 | $15 | $1.73M | 13 | 2023-07-07 |
| CONTRAFECT Corp (CFRX) Delisted | Director | 1,020 | $0.05 | $51 | $49.6K | 8 | 2022-05-18 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Director | — | $2.93 | — | $0 | 3 | 2021-06-17 |
| GNMX | Director | 1,181,878 | $29.99 | $35.44M | $2.74M | 8 | 2019-12-09 |
| PDSB | Director | 678,075 | $0.69 | $468.3K | $0 | 1 | 2019-03-18 |
| EDGE | Director | 32,904 | $49.76 | $1.64M | $495.0K | 6 | 2018-08-15 |
| InspireMD, Inc. (NSPR.WS) Delisted | Director | — | $0.05 | — | $0 | 1 | 2016-12-08 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Director | 0 | — | — | $0 | 6 | 2016-11-30 |
| NSPR | Director | 2 | $0.68 | $1 | $2.31M | 22 | 2016-07-11 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 45,000 | $14.49 | $652.0K | $167.6K | 10 | 2016-06-13 |
| CONTRAFECT Corp (CFRX.W) Delisted | Director | — | — | — | $0 | 1 | 2016-05-10 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | Director | — | — | — | $0 | 1 | 2016-04-19 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Director | 560,846 | — | — | $4.69M | 15 | 2015-10-08 |
| CONTRAFECT Corp (CFRX.Z) Delisted | Director | — | — | — | $0 | 2 | 2015-05-06 |
| CELGENE CORP /DE/ (CELGZ) Delisted | Director | 828,673 | — | — | -$4.32M | 2 | 2011-01-14 |
| CELGENE CORP /DE/ (CELG) Delisted | Executive Chairman | 1,621,082 | — | — | -$136.24M | 26 | 2010-10-14 |
Recent Filings · Page 3 of 16
157 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-12-22 | NexImmune, Inc. (NEXI) Delisted | Exer (M) | +50,000 | $258.5K | EDGAR |
| 2021-06-17 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-16 | TEVA | Grant (A) | — | $0 | EDGAR |
| 2021-06-10 | TEVA | Exer (M) | +22,565 | $0 | EDGAR |
| 2021-06-08 | TEVA | Exer (M) | +17,565 | $0 | EDGAR |
| 2021-05-20 | CONTRAFECT Corp (CFRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-19 | NexImmune, Inc. (NEXI) Delisted | Mixed | +2,555,765 | $1.02M | EDGAR |
| 2021-02-16 | NexImmune, Inc. (NEXI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-13 | TEVA | Exer (M) | +23,133 | $0 | EDGAR |
| 2020-06-19 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.